Michael Lanuti, MD
Michael Lanuti, MD
Director, Thoracic Oncology, Division of Thoracic Surgery
Associate Professor Harvard Medical School
Departments, Centers, & Programs:
Cooley Dickinson Hospital
30 Locust St.
Northampton, MA 01061
- MD, University of Pennsylvania School of Medicine
- Residency, Hospital of the Univ of Pennsylvania
- Residency, Hospital of the University of Pennsylvania
- Fellowship, Harvard Medical School
American Board Certifications
- Surgery, American Board of Surgery
- Thoracic and Cardiac Surgery, American Board of Thoracic Surgery
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Lanuti spearheads translational research in a Thoracic Oncology Research Laboratory. The principle goals of the laboratory are to design novel therapeutics to treat lung and esophageal cancer that can be brought to clinical trials. The laboratory uses oncolytic viruses in combination with other modalities such as chemotherapy and angiotensin system inhibitors to target solid tumor. Some of these strategies include development of oncolytic viruses that help degrade tumor matrix. Ultimately, this translational effort will strive to bring treatment strategies from the laboratory bench to the bedside and back to the bench again for re-evaluation and improvement.
Another lab interest is molecular imaging of pulmonary fibrosis. We have pioneered the first collagen-PET probe to be used in the quantitation of patients carrying a diagnosis of pulmonary fibrosis. This same technology is being studied in a clinical trial to better characterize radiation induced lung injury which may ultimately be used to help differentiate lung injury from tumor recurrence.
Stage I non small cell lung cancer can still recur with a 25% chance of relapse despite complete resection. Dr. Lanuti is investigating the role of driver mutations and gene signatures to stratify risk of recurrence in resected stage I lung adenocarcinoma. This work can contribute to adjuvant therapies for high risk resected stage I lung cancers.
Dr. Lanuti has investigated molecular risk factors for esophageal adenocarcinoma and found an elevated risk associated with single nucleotide polymorphisms in the epidermal growth factor (EGF) gene which is associated with differentiation of tumor tissue.
- Costantino CL, Geller AD, Wright CD, Ott HC, Muniappan A, Mathisen DJ, Lanuti M. Carinal surgery: A single-institution experience spanning 2 decades. J Thorac Cardiovasc Surg. 2018 Dec 15.
- Geller, AD, Zheng H, Gaissert HA, Mathisen DJ, Muniappan A, Wright CD, Lanuti M. Relative Incremental Cost of Postoperative Complications of Esophagectomy. Sem Thor Cardiovasc Surg. 2019 Summer;31(2):290-299.
- Geller AD, Zheng H, Mathisen DJ, Wright CD, Lanuti M. Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018 Apr;155(4):1804-1811.
- Désogère P, Tapias LF, Hariri LP, Rotile N, Rietz TA, Probst CK, Blasi F, Day H, Elliot J, Mino-Kenudson M, Weinreb P, Violette SM, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Science Trans Med. 2017 Apr 5;9(384).
- Izar B, Sequist L, Lee M, Muzikansky A, Heist RS, Iafrate AJ, Dias-Santagata D, Mathisen DJ, Lanuti M. Impact of EGFR mutation status on outcomes in patients with resected stage I NSLC. Ann Thorac Surg. 2013 Sep;96(3):962-8.
- Sharma A, Willers H, Digumarthy SR, Mathisen DJ, Shepard JO. Radiofrequency ablation for stage I non small cell lung cancer: management of loco-regional recurrence. Ann Thorac Surg, 2012 Mar;93(3):921-8.